The optimum therapy for @entity1 with relapsed or @entity1893 ( @entity1893 ) not qualifying for @entity902 -based and/or high-dose chemotherapy is not known. We conducted a prospective phase II study evaluating a regimen consisting of @entity136 (1 g/m2, days 1 and 8), @entity1206 (30 mg/m2, days 1 and 8) and @entity229 (100 mg/day, days 1-8) (GVP) given every 21 days. Fifteen @entity1 with a median age of 68 years and a median of three previous therapies were enrolled. Diagnoses included B lymphoblastic (n=1), diffuse large B cell (n=10), anaplastic large T cell (n=2) and peripheral T-cell @entity1893 (n=2). The median international prognostic index score was 3 (six @entity1 with a score of 4 or 5). Five @entity1 achieved a complete remission and three @entity1 a partial remission. The median overall survival was 13.8 months, and the median time to next treatment was 4.4 months. @entity137 of World Health Organisation grades 3/4 were @entity1210 in 58%, @entity882 in 33% and @entity417 in 17% of all courses. Three @entity1 had grade 3 @entity281 . There was no treatment-related mortality. GVP shows substantial activity in poor prognosis relapsed or @entity146 and is generally well tolerated, but haematological @entity137 is dose limiting.

@entity136 , @entity1206 and @entity229 for refractory or relapsed XXXX , results of a phase II single center study.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'Haematological toxicities'] @entity417 :: ('MESH:D000740', 'Disease') :: ['anaemia'] @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity146 :: ('MESH:D001523', 'Disease') :: ['refractory aggressive lymphomas'] @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone'] @entity1206 :: ('MESH:C030852', 'Chemical') :: ['vinorelbine'] @entity281 :: ('MESH:D007239', 'Disease') :: ['infections'] @entity1893 :: ('MESH:D008228', 'Disease') :: ['NHL', "refractory aggressive non-Hodgkin's lymphomas"] @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine'] @entity1210 :: ('MESH:C536227', 'Disease') :: ['leucopenia']
@entity146 :: (MESH:D001523,Disease) :: ['aggressive lymphoma']
